Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Caso contributivo

PDF MeBrain

Una strana pancitopenia: dalla gestione in urgenza alla diagnosi genetica

A strange Pancytopenia: from emergency management to genetic diagnosis

Michela Di Filippo1, Lisa Rossoni1, Marta Nebiolo1, Francesca Fioredda2, Valentina Carrato3, Daniela Pirlo3
1Dipartimento Di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), Università di Genova
2UOC Ematologia, 3UOC Terapia Intensiva e Semintensiva Neonatale e Pediatrica, IRCCS “Giannina Gaslini”, Genova

Dicembre 2024 | DOI: 10.53126/MEBXXVIID201

Abstract
Wiskott-Aldrich syndrome (WAS) is a rare X-linked genetic disorder caused by a mutation in the WAS gene that codes for the WASp protein, which is involved in the functioning of the cytoskeleton of non-erythroid haematopoietic cells. This mutation leads to a congenital immunity disorder characterised by immunodeficiency, micro-thrombocytopenia and eczema. Its incidence is 1 in 250,000 live-born males. Treatment options to date are haematopoietic stem cell transplantation (HSCT) from an HLA-matched donor or gene therapy. The paper described the case of a 5-month-old first-born child with WAS who represented a diagnostic challenge. At onset, the infant did not present with any pathognomonic elements of classic WAS, but a picture of trilinear cytopenia with severe anaemia. Only one single case is described in literature with the same genotype (WAS c.257G>A p. Arg86His) but characterised by a heterogeneous phenotype and different onset symptoms. The specific and timely diagnosis of WAS allowed the patient, at only 5 months of age, to undergo gene therapy, thus achieving a real recovery from the syndrome and significantly reducing the risks related to the toxicity of non-targeted therapies to which he would have been ex-posed in the future.
Riassunto
La sindrome di Wiskott–Aldrich (WAS) è una rara malattia genetica X-linked causata da mutazioni del gene WAS che codifica per la proteina WASP, coinvolta nel funzionamento del citoscheletro delle cellule ematopoietiche non eritroidi. Tali mutazioni determinano un deficit congenito dell’immunità caratterizzato da immunodeficienza, microtrombocitopenia ed eczema. L’incidenza è di 1 su 250.000 maschi nati vivi. Le opzioni terapeutiche a oggi perseguibili sono il trapianto di cellule staminali ematopoietiche (HSCT) da donatore HLA (Human Leukocyte Antigen) compatibile o la terapia genica. Presentiamo il caso di un bambino di 5 mesi con un quadro di citopenia trilineare con anemia severa, in assenza degli elementi patognomonici di WAS classica. In letteratura è descritto un singolo caso presentante il medesimo genotipo qui osservato, ma caratterizzato da fenotipo eterogeneo e sintomi d’esordio dissimili. La diagnosi di WAS specifica e tempestiva ha permesso di riferire il lattante presso altro centro per l’avvio della terapia genica, puntando alla reale guarigione dalla sindrome e riducendo sensibilmente i rischi correlati alla tossicità delle cure non mirate a cui sarebbe stato sottoposto nel futuro.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48(2):124-31. DOI: 10.1002/pbc.21039.
  2. Cavannaugh C, Ochs HD, Buchbinder D. Diagnosis and clinical management of Wiskott-Aldrich syndrome: current and emerging techniques. Expert Rev Clin Immunol 2022;18(6):609-23. DOI: 10.1080/1744666X.2022.2074400.
  3. Notarangelo LD, Miao CH, Ochs HD. Wiskott- Aldrich syndrome. Curr Opin Hematol 2008;15(1):30-6. DOI: 10.1097/MOH.0b013e 3282f30448.
  4. Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood 1980;55(2):243. DOI: 10.1182/blood.V55.2.243.243.
  5. Wada T, Itoh M, Maeba H, et al. Intermittent X- linked thrombocytopenia with a novel WAS gene mutation. Pediatr Blood Cancer 2014;61(4):746-8. DOI: 10.1002/pbc.24787.
  6. Kanazawa T, Ishida T, Shirai M, et al. Wiskott- Aldrich syndrome with normal-sized platelets. Pediatr Int 2023;65(1): e15453. DOI: 10.1111/ ped.15453.
  7. Calzoni E, Castagnoli R, Giardino G, et al. I Disordini Atopici primari: come riconoscerli e intervenire. Rivista di Immunologia e Allergologia Pediatrica 2022;36(02):I-XVI. DOI 10.53151/2531-3916/2022-8.
  8. Maillard MH, Cotta-de-Almeida V, Takeshima F, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+) Foxp3(+) regulatory T cells. J Exp Med 2007;204(2):381-91. DOI: 10.1084/jem.20061338.
  9. Humblet-Baron S, Sather B, Anover S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest 2007;117(2):407-18. DOI: 10.1172/JCI29539.
  10. Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood 1993;82(10):2961. DOI: 10.1182/blood.V82.10.2961.296.
  11. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994;125(6 Pt 1):876-85. DOI: 10.1016/s0022-3476(05)82002-5.
  12. Albert MH, Bittner TC, Nonoyama S, et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010;115(16):3231-8. DOI: 10.1182/blood-2009-09-239087.
  13. Candotti, F. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome. J Clin Immunol 2018; 38(1): 13-27. DOI: 10.1007/s10875-017-0453-z.
  14. Cannioto Z, Berti I, Martelossi S, et al. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur J Pediatr 2009;168(2):149-55. DOI: 10.1007/s00431-008-0721-2.
  15. Sprenkeler EGG, Webbers SDS, Kuijpers TW. When Actin is Not Actin' Like It Should: A New Category of Distinct Primary Immunodeficiency Disorders. J Innate Immun 2021;13(1):3-25. DOI: 10.1159/000509717.
  16. Rivers E, Worth A, Thrasher AJ, Burns SO. How I manage patients with Wiskott Aldrich syndrome. Br J Haematol 2019;185(4):647-55. DOI: 10.1111/bjh.15831.
  17. Gabelli M, Marzollo A, Notarangelo LD, Basso G, Putti MC. Eltrombopag use in a patient with Wiskott-Aldrich syndrome. Pediatr Blood Cancer 2017;64(12). DOI: 10.1002/pbc.26692.
  18. Gerrits AJ, Leven EA, Frelinger AL 3rd, et al. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood 2015;126(11):1367-78. DOI: 10.1182/blood-2014-09-602573.
  19. Khoreva A, Abramova I, Deripapa E, et al. Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome. Br J Haematol 2021;192(2):366-74. DOI: 10.1111/bjh.17174.
  20. Carlsson G, Ahlin A, Dahllöf G, Elinder G, Henter JI, Palmblad J. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia. Br J Haematol 2004;126(1):127-32. DOI: 10.1111/j.1365-2141.2004.05008.x.
  21. Blaese RM, Strober W, Levy AL, Waldmann TA. Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. J Clin Invest 1971; 50(11): 2331-8. DOI: 10.1172/JCI106731.
  22. Magnani A, Semeraro M, Adam F, et al. Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome. Nat Med 2022;28(1):71-80. DOI: 10.1038/s41591-021-01641-x.
  23. Ferrua F, Cicalese MP, Galimberti S, et al. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Lancet Haematol 2019;6(5): e239-e253. DOI: 10.1016/S2352-3026(19)30021-3.
  24. Labrosse R, Chu JI, Armant MA, et al. Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood 2023;142(15):1281-96. DOI: 10.1182/blood.2022019117.
  25. Park SK, Kim CS, Song DK, Kim JY, Choi IJ, Kim DK. A familial case of Wiskott-Aldrich Syndrome with a hotspot mutation in exon 2 of the WAS Gene. J Korean Med Sci 2007;22(6):998-1001. DOI: 10.3346/jkms.2007.22.6.998.